Global Antibody-oligonucleotide Conjugates (AOCs) Market Growth (Status and Outlook) 2025-2031

According to this study, the global Antibody-oligonucleotide Conjugates (AOCs) market size will reach US$ 1446 million by 2031.

AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.

The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.

The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Regionally, North America accounts for more than 60% of the market share thanks to FDA accelerated approval and biotechnology clusters, while Asia Pacific relies on CDMO companies such as WuXi Biologics to enter the production link. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.

This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-oligonucleotide Conjugates (AOCs) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Chemical Coupling
Enzymatic Coupling

Segmentation by Application:
Pharmaceuticals
Scientific Research

This report also splits the market by region:
United States
China
Europe
Other regions
Japan
South Korea
Southeast Asia
Rest of world

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:
Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Creative Biolabs
Abzena
BOCSCI Inc.
Wuxi AppTec
Lonza
Leinco

Please note: The report will take approximately 2 business days to prepare and deliver.